(Q46603181)

23 December 2017

title

Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer (English)

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

5 December 2022

1 reference

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

5 December 2022

author name string

G. Falkson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1832906

5 December 2022

D. C. Tormey

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1832906

5 December 2022

P. Carey

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1832906

5 December 2022

R. Witte

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1832906

5 December 2022

H. C. Falkson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1832906

5 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1832906

5 December 2022

publication date

1 January 1991

1 reference

23 December 2017

full work available at URL

https://api.elsevier.com/content/article/PII:027753799190261B?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

https://api.elsevier.com/content/article/PII:027753799190261B?httpAccept=text/plain

5 December 2022

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

European Journal of Cancer

5 December 2022

published in

1 reference

23 December 2017

volume

27

1 reference

23 December 2017

issue

8

1 reference

23 December 2017

page(s)

973-977

1 reference

23 December 2017

A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

5 December 2022

3

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard

5 December 2022

5

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer

5 December 2022

6

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy

5 December 2022

7

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

Proceedings: Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer

5 December 2022

8

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project

5 December 2022

9

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. A randomized trial

5 December 2022

10

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

Chemotherapy of advanced breast cancer: a randomized trial of vincristine, Adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP)

5 December 2022

11

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin

5 December 2022

12

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer

5 December 2022

13

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

Combination chemotherapy for advanced breast cancer: two regimens containing adriamycin

5 December 2022

14

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer

5 December 2022

15

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial

5 December 2022

17

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

Age as a prognostic factor in recurrent breast cancer

5 December 2022

18

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study.

5 December 2022

19

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90261-B

5 December 2022

Identifiers

1 reference

23 December 2017

1 reference

23 December 2017